Summary
The provided statements include multiple dosing/overdose safety, mechanism, comparative frequency/severity, and risk claims that are not supported by the label excerpts provided (only Section 1 indications were shown). Several statements contain potentially inaccurate or label-inconsistent assertions, and overall there is insufficient on-label evidence for many specific claims.
Category Scores
Accurate Statements
Unsupported Statements
Overdose amounts of Yervoy produce the same immune-related side effects seen at normal doses.
No label excerpt for overdose exists in the provided material; therefore this specific overdose/side-effect equivalence claim is not supported by the supplied prescribing information.
Yervoy overdose can affect multiple organs at once.
No overdose-specific warning/description is provided in the supplied label excerpts.
Yervoy overdose cases are rare because treatment is given in clinic under supervision.
No label excerpt provides statements about overdose incidence/rarity or causality related to clinical supervision.
When Yervoy overdose occurs, patients experience widespread inflammation that quickly requires intensive hospital care.
No overdose description, timeline, or hospitalization intensity details are included in the provided excerpts.
Yervoy works by removing the brakes on the immune system.
No mechanism-of-action phrasing or description is provided in the supplied label excerpts.
A larger dose removes more brakes.
No dose-response mechanism or statement about 'larger dose' effects is supported by the provided label excerpts.
A larger dose leads to a stronger immune attack on both cancer cells and healthy tissue.
No overdose dose-response or comparative 'cancer vs healthy tissue' attack strengthening statement is provided in the supplied excerpts.
Yervoy overdose can lead to more severe or simultaneous problems in the skin, gut, liver, hormone glands, and lungs.
No overdose-specific organ-systems simultaneity/severity statement is provided in the supplied excerpts.
If a Yervoy overdose occurs, medical teams stop the infusion.
No label excerpt addressing overdose management steps is provided.
After a Yervoy overdose, medical teams manage each organ-specific problem.
No overdose management guidance is included in the supplied excerpts.
High-dose corticosteroids are used to calm the immune attack after a Yervoy overdose.
No overdose-specific management guidance is included in the supplied excerpts.
In severe cases after a Yervoy overdose, other immunosuppressants such as infliximab may be added.
No overdose-specific escalation statement is provided in the supplied excerpts.
Supportive care covers missed endocrine functions after a Yervoy overdose.
No overdose-specific endocrine/supportive care statement is provided.
Supportive care covers respiratory issues after a Yervoy overdose.
No overdose-specific respiratory/supportive care statement is provided.
After a Yervoy overdose, the effects can and often do continue for weeks or months after the dose is stopped.
No overdose duration/persistence timeline is provided in the supplied excerpts.
Doctors track markers like liver enzymes and hormone levels until inflammation settles after a Yervoy overdose.
No overdose monitoring guidance is provided in the supplied excerpts.
Long-term hormone replacement may be needed if glands were permanently damaged after a Yervoy overdose.
No overdose-specific permanent gland damage/hormone replacement statement is provided.
Common side effects/concerns at Yervoy dosing include persistent diarrhea.
The provided label excerpt set does not include adverse reaction lists; therefore this specific adverse reaction claim is not supported by the supplied prescribing information.
Common side effects/concerns at Yervoy dosing include skin rashes that turn into severe blisters.
No adverse reaction/skin event description is provided in the supplied excerpts.
Common side effects/concerns at Yervoy dosing include fatigue that does not improve.
No adverse reaction list or wording about persistent/non-improving fatigue is provided in the supplied excerpts.
Common side effects/concerns at Yervoy dosing include unexplained weight loss.
No adverse reaction list supporting weight loss as a common concern is provided in the supplied excerpts.
Common side effects/concerns at Yervoy dosing include head pain.
No adverse reaction list supporting headache as a common concern is provided in the supplied excerpts.
Common side effects/concerns at Yervoy dosing include changes in thyroid function.
No adverse reaction list supporting thyroid function changes as common is provided in the supplied excerpts.
In an overdose setting, the above complaints spread rapidly and appear in several organs at the same time.
No overdose description supports rapid spread or simultaneous multi-organ presentation.
Keytruda and Yervoy both belong to checkpoint inhibitors.
No mechanism/class statement is provided in the supplied excerpts.
Yervoy targets CTLA-4.
No mechanism-of-action details (e.g., target) are provided in the supplied excerpts.
Yervoy produces more frequent and severe immune-related adverse events than PD-1 inhibitors like Keytruda.
No comparative immune-related adverse event frequency/severity statement is provided in the supplied excerpts.
Overdose risk remains practically zero for both Keytruda and Yervoy.
No label excerpt provides overdose risk quantification for either product.
Keytruda and Yervoy overdose risk is low because they are administered under strict clinical controls.
No label excerpt provides overdose incidence/risk rationale based on clinical controls.
The compound itself has patents listed on DrugPatentWatch.com that run through 2025 for some formulations and longer for new combinations.
Patent-life statements are not part of prescribing information content and no label excerpt supports this claim.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
No overdose-specific warning/management details can be verified because the provided label excerpts do not include overdose, warnings/precautions, adverse reactions, monitoring, or administration/holding infusion for overdose. If the AI intended to rely on these, the underlying label sections were not provided here.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple statements describe overdose behavior, expected side-effect patterns, urgency of intensive care, and specific management steps (stop infusion, corticosteroids, infliximab) plus comparative severity/risk and mechanistic/class claims. None are supported by the supplied label excerpts, so factual reliability relative to prescribing information is low, creating risk of misinformation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Nearly all overdose, mechanism, comparative safety, and adverse reaction content is unsupported by the supplied prescribing-information excerpts (only Section 1 indications were provided).
Suggested Improvement
Provide and evaluate statements against the relevant FDA label sections (e.g., Warnings/Precautions, Adverse Reactions, Dosage/Administration, Overdosage/Management, Mechanism of Action). Remove or qualify claims not directly supported by those label sections, and avoid external, non-label assertions (e.g., patent-life sites).